288 related articles for article (PubMed ID: 34349010)
1. Association of Midlife Plasma Amyloid-β Levels With Cognitive Impairment in Late Life: The ARIC Neurocognitive Study.
Sullivan KJ; Blackshear C; Simino J; Tin A; Walker KA; Sharrett AR; Younkin S; Gottesman RF; Mielke MM; Knopman D; Windham BG; Griswold ME; Mosley TH
Neurology; 2021 Sep; 97(11):e1123-e1131. PubMed ID: 34349010
[TBL] [Abstract][Full Text] [Related]
2. Ten-year change in plasma amyloid beta levels and late-life cognitive decline.
Okereke OI; Xia W; Selkoe DJ; Grodstein F
Arch Neurol; 2009 Oct; 66(10):1247-53. PubMed ID: 19822780
[TBL] [Abstract][Full Text] [Related]
3. The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment.
Fei M; Jianghua W; Rujuan M; Wei Z; Qian W
J Neurol Sci; 2011 Jun; 305(1-2):92-6. PubMed ID: 21440911
[TBL] [Abstract][Full Text] [Related]
4. Association of Plasma Aβ
Johnson EL; Sullivan KJ; Schneider ALC; Simino J; Mosley TH; Kucharska-Newton A; Knopman DS; Gottesman RF
Neurology; 2023 Sep; 101(13):e1319-e1327. PubMed ID: 37541842
[TBL] [Abstract][Full Text] [Related]
5. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.
Graff-Radford NR; Crook JE; Lucas J; Boeve BF; Knopman DS; Ivnik RJ; Smith GE; Younkin LH; Petersen RC; Younkin SG
Arch Neurol; 2007 Mar; 64(3):354-62. PubMed ID: 17353377
[TBL] [Abstract][Full Text] [Related]
6. Proteomic Analysis Identifies Circulating Proteins Associated With Plasma Amyloid-β and Incident Dementia.
Tin A; Sullivan KJ; Walker KA; Bressler J; Talluri R; Yu B; Simino J; Gudmundsdottir V; Emilsson V; Jennings LL; Launer L; Mei H; Boerwinkle E; Windham BG; Gottesman R; Gudnason V; Coresh J; Fornage M; Mosley TH
Biol Psychiatry Glob Open Sci; 2023 Jul; 3(3):490-499. PubMed ID: 37519456
[TBL] [Abstract][Full Text] [Related]
7. Identification and Preliminary Validation of a Plasma Profile Associated with Cognitive Decline in Dementia and At-Risk Individuals: A Retrospective Cohort Analysis.
Iulita MF; Ganesh A; Pentz R; Flores Aguilar L; Gubert P; Ducatenzeiler A; Christie S; Wilcock GK; Cuello AC
J Alzheimers Dis; 2019; 67(1):327-341. PubMed ID: 30636741
[TBL] [Abstract][Full Text] [Related]
8. Relation between insulin, insulin-related factors, and plasma amyloid beta peptide levels at midlife in a population-based study.
Townsend MK; Okereke OI; Xia W; Yang T; Selkoe DJ; Grodstein F
Alzheimer Dis Assoc Disord; 2012; 26(1):50-4. PubMed ID: 21502851
[TBL] [Abstract][Full Text] [Related]
9. Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers.
Hanon O; Vidal JS; Lehmann S; Bombois S; Allinquant B; Tréluyer JM; Gelé P; Delmaire C; Blanc F; Mangin JF; Buée L; Touchon J; Hugon J; Vellas B; Galbrun E; Benetos A; Berrut G; Paillaud E; Wallon D; Castelnovo G; Volpe-Gillot L; Paccalin M; Robert PH; Godefroy O; Dantoine T; Camus V; Belmin J; Vandel P; Novella JL; Duron E; Rigaud AS; Schraen-Maschke S; Gabelle A;
Alzheimers Dement; 2018 Jul; 14(7):858-868. PubMed ID: 29458036
[TBL] [Abstract][Full Text] [Related]
10. Plasma Aβ and PET PiB binding are inversely related in mild cognitive impairment.
Devanand DP; Schupf N; Stern Y; Parsey R; Pelton GH; Mehta P; Mayeux R
Neurology; 2011 Jul; 77(2):125-31. PubMed ID: 21715709
[TBL] [Abstract][Full Text] [Related]
11. Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes.
Verberk IMW; Slot RE; Verfaillie SCJ; Heijst H; Prins ND; van Berckel BNM; Scheltens P; Teunissen CE; van der Flier WM
Ann Neurol; 2018 Nov; 84(5):648-658. PubMed ID: 30196548
[TBL] [Abstract][Full Text] [Related]
12. Elevation of Plasma Amyloid-β Level is More Significant in Early Stage of Cognitive Impairment: A Population-Based Cross-Sectional Study.
Wang J; Qiao F; Shang S; Li P; Chen C; Dang L; Jiang Y; Huo K; Deng M; Wang J; Qu Q
J Alzheimers Dis; 2018; 64(1):61-69. PubMed ID: 29865072
[TBL] [Abstract][Full Text] [Related]
13. Whole exome sequence-based association analyses of plasma amyloid-β in African and European Americans; the Atherosclerosis Risk in Communities-Neurocognitive Study.
Simino J; Wang Z; Bressler J; Chouraki V; Yang Q; Younkin SG; Seshadri S; Fornage M; Boerwinkle E; Mosley TH
PLoS One; 2017; 12(7):e0180046. PubMed ID: 28704393
[TBL] [Abstract][Full Text] [Related]
14. Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging.
Mielke MM; Hagen CE; Wennberg AMV; Airey DC; Savica R; Knopman DS; Machulda MM; Roberts RO; Jack CR; Petersen RC; Dage JL
JAMA Neurol; 2017 Sep; 74(9):1073-1080. PubMed ID: 28692710
[TBL] [Abstract][Full Text] [Related]
15. Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status.
Palmqvist S; Janelidze S; Stomrud E; Zetterberg H; Karl J; Zink K; Bittner T; Mattsson N; Eichenlaub U; Blennow K; Hansson O
JAMA Neurol; 2019 Sep; 76(9):1060-1069. PubMed ID: 31233127
[TBL] [Abstract][Full Text] [Related]
16. Associations Between Midlife Vascular Risk Factors and 25-Year Incident Dementia in the Atherosclerosis Risk in Communities (ARIC) Cohort.
Gottesman RF; Albert MS; Alonso A; Coker LH; Coresh J; Davis SM; Deal JA; McKhann GM; Mosley TH; Sharrett AR; Schneider ALC; Windham BG; Wruck LM; Knopman DS
JAMA Neurol; 2017 Oct; 74(10):1246-1254. PubMed ID: 28783817
[TBL] [Abstract][Full Text] [Related]
17. Elevated Plasma Aβ42 in Cognitively Impaired Individuals Taking ACE Inhibitor Antihypertensives.
Regenold WT; Blumenthal JB; Loreck DJ; Mordecai KL; Scarinzi G; Doddi SR; Adler L
Am J Alzheimers Dis Other Demen; 2017 Sep; 32(6):347-352. PubMed ID: 28449585
[TBL] [Abstract][Full Text] [Related]
18. Midlife vascular risk factors and midlife cognitive status in relation to prevalence of mild cognitive impairment and dementia in later life: The Atherosclerosis Risk in Communities Study.
Knopman DS; Gottesman RF; Sharrett AR; Tapia AL; DavisThomas S; Windham BG; Coker L; Schneider ALC; Alonso A; Coresh J; Albert MS; Mosley TH
Alzheimers Dement; 2018 Nov; 14(11):1406-1415. PubMed ID: 29763593
[TBL] [Abstract][Full Text] [Related]
19. Association of plasma β-amyloid 40 and 42 concentration with type 2 diabetes among Chinese adults.
Peng X; Xu Z; Mo X; Guo Q; Yin J; Xu M; Peng Z; Sun T; Zhou L; Peng X; Xu S; Yang W; Bao W; Shan Z; Li X; Liu L
Diabetologia; 2020 May; 63(5):954-963. PubMed ID: 32034441
[TBL] [Abstract][Full Text] [Related]
20. A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer's disease.
Shahpasand-Kroner H; Klafki HW; Bauer C; Schuchhardt J; Hüttenrauch M; Stazi M; Bouter C; Wirths O; Vogelgsang J; Wiltfang J
Alzheimers Res Ther; 2018 Dec; 10(1):121. PubMed ID: 30526652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
